- Home
- STTK vs ECOR Comparison
STTK vs ECOR Comparison
Compare STTK & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ECOR
- Stock Information
- Founded
- STTK 2016
- ECOR 2005
- Country
- STTK United States
- ECOR United States
- Employees
- STTK 44
- ECOR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- STTK Health Care
- ECOR Health Care
- Exchange
- STTK Nasdaq
- ECOR Nasdaq
- Market Cap
- STTK 48.9M
- ECOR 39.7M
- IPO Year
- STTK 2020
- ECOR 2018
- Fundamental
- Price
- STTK $1.02
- ECOR $4.96
- Analyst Decision
- STTK Hold
- ECOR Strong Buy
- Analyst Count
- STTK 5
- ECOR 2
- Target Price
- STTK $2.00
- ECOR $25.50
- AVG Volume (30 Days)
- STTK 5.2M
- ECOR 118.9K
- Earning Date
- STTK 08-14-2025
- ECOR 08-06-2025
- Dividend Yield
- STTK N/A
- ECOR N/A
- EPS Growth
- STTK N/A
- ECOR N/A
- EPS
- STTK N/A
- ECOR N/A
- Revenue
- STTK $2,997,000.00
- ECOR $27,700,000.00
- Revenue This Year
- STTK N/A
- ECOR $23.21
- Revenue Next Year
- STTK N/A
- ECOR $44.10
- P/E Ratio
- STTK N/A
- ECOR N/A
- Revenue Growth
- STTK N/A
- ECOR 30.16
- 52 Week Low
- STTK $0.69
- ECOR $4.16
- 52 Week High
- STTK $3.95
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- STTK 61.64
- ECOR 39.06
- Support Level
- STTK $0.71
- ECOR $4.16
- Resistance Level
- STTK $1.05
- ECOR $5.58
- Average True Range (ATR)
- STTK 0.09
- ECOR 0.52
- MACD
- STTK 0.03
- ECOR -0.11
- Stochastic Oscillator
- STTK 69.18
- ECOR 24.76
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.